We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Sets Dissolution Specs for Immediate-Release Drugs
U.S. FDA Sets Dissolution Specs for Immediate-Release Drugs
Manufacturers of highly soluble immediate-release tablets and capsules may use standard release tests instead of method development and specification-setting exercises to show how quickly the drug dissolves, the U.S. Food and Drug Administration says in draft guidance released July 31.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor